Alvotech opened lower at $4.50, compared with its previous close of $4.92. In the last trading session, the stock traded between $4.31 and $4.76. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Alvotech is now worth
$ 41.90
Resulting in a loss of
$ 58.10 (58.10%)
Invest with $1
Note: Past profits do not guarantee future returns.
Q3 EPS of $(0.23) missed consensus estimate of $0.07 by 228%. Nine-month adjusted revenue fell 23% YoY to $323.4 million. Adjusted EBITDA rose 15.1% YoY to $78.3 million for the nine months. Full-year 2026 revenue guidance maintained at $650-$700 million.
Yesterday
12Nov
Alvotech FY26 Results: Sales guidance held at $650M-$700M
Alvotech affirms FY26 sales guidance of $650.000 million to $700.000 million. Guidance range remains unchanged from previous outlook. Lower bound of guidance is $650.000 million vs $651.278 million estimate. Upper bound of guidance stands at $700.000 million.
Yesterday
10Nov
Jefferies initiates coverage on Alvotech with Buy rating, sets $9 target
Jefferies initiated coverage on Alvotech with a Buy rating. Price target set at $9 per share. Coverage initiated by analyst Dennis Ding.
2 days ago
20Oct
Alvotech secures FDA approval for process doubling SIMLANDI output
FDA approves Process 2.0 for SIMLANDI production in Iceland. New method doubles drug substance output per batch. Upstream manufacturing scale remains unchanged. Enhanced capacity supports other portfolio products.
23 days ago
14Oct
Alvotech submits first global biosimilar application for Eylea 8mg
First global regulatory submission for a biosimilar to Eylea 8 mg filed with the European Medicines Agency. High-dose formulation reduces treatment intervals from eight weeks to 16 weeks for certain patients. 8 mg variant captured ~57% of global Eylea sales value in Q2 2026, up from ~30% in Q2 2025. Alvotech handles development and supply; Advanz Pharma manages European commercialization.
29 days ago
7Oct
Alvotech enters long-term biosimilar manufacturing pact with LOTTE
Alvotech signs long-term manufacturing deal with LOTTE Biologics. Production located at Syracuse, New York facility with 40,000 liters capacity. Facility recently passed unannounced FDA inspection with zero observations. Partnership supports global supply of multiple antibody biosimilar products.
